An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence

Insights into Imaging - Tập 10 - Trang 1-16 - 2019
Kevin Kalisz1, Francesco Alessandrino2,3, Rose Beck4, Daniel Smith5, Elias Kikano5, Nikhil H. Ramaiya5, Sree Harsha Tirumani2,3,5
1Department of Radiology, Duke University, Durham, USA
2Department of Imaging, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
3Department of Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
4Department of Pathology, UH Cleveland Medical Center, Case Western Reserve University, Cleveland, USA
5Department of Radiology, UH Cleveland Medical Center, Case Western Reserve University, Cleveland, USA

Tóm tắt

Burkitt lymphoma (BL) is a highly aggressive, rapidly growing B cell non-Hodgkin lymphoma, which manifests in several subtypes including sporadic, endemic, and immunodeficiency-associated forms. Pathologically, BL is classically characterized by translocations of chromosomes 8 and 14 resulting in upregulation of the c-myc protein transcription factor with upregulation of cell proliferation. BL affects nearly every organ system, most commonly the abdomen and pelvis in the sporadic form. Imaging using a multimodality approach plays a crucial role in the management of BL from diagnosis, staging, and evaluation of treatment response to therapy-related complications with ultrasound, computed tomography, magnetic resonance imaging, and positron emission tomography playing roles. In this article, we review the pathobiology and classification of BL, illustrate a multimodality imaging approach in evaluating common and uncommon sites of involvement within the trunk and head and neck, and review common therapies and treatment-related complications.

Tài liệu tham khảo

Mbulaiteye SM, Anderson WF, Ferlay J et al (2012) Pediatric, elderly, and emerging adult-onset peaks in Burkitt's lymphoma incidence diagnosed in four continents, excluding Africa. Am J Hematol 87(6):573–578. https://doi.org/10.1002/ajh.23187 Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107(1):265–276. https://doi.org/10.1182/blood-2005-06-2508 Ferry JA (2006) Burkitt’s lymphoma: clinicopathologic features and differential diagnosis. Oncologist 11(4):375–383. https://doi.org/10.1634/theoncologist.11-4-375 Ogwang MD, Bhatia K, Biggar RJ, Mbulaiteye SM (2008) Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited. Int J Cancer 123(11):2658–2663. https://doi.org/10.1002/ijc.23800 Magrath I (2012) Epidemiology: clues to the pathogenesis of Burkitt lymphoma. Br J Haematol 156(6):744–756. https://doi.org/10.1111/j.1365-2141.2011.09013.x Brady G, MacArthur GJ, Farrell PJ (2007) Epstein-Barr virus and Burkitt lymphoma. J Clin Pathol 60(12):1397–1402. https://doi.org/10.1136/jcp.2007.047977 Schmitz R, Ceribelli M, Pittaluga S, Wright G, Staudt LM (2014) Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med 4(2). https://doi.org/10.1101/cshperspect.a014282 O’Malley DP, Auerbach A, Weiss LM (2015) Practical applications in immunohistochemistry: evaluation of diffuse large B-cell lymphoma and related large B-cell lymphomas. Arch Pathol Lab Med 139(9):1094–1107. https://doi.org/10.5858/arpa.2014-0451-CP Sesques P, Johnson NA (2017) Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. Blood 129(3):280–288. https://doi.org/10.1182/blood-2016-02-636316 Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390. https://doi.org/10.1182/blood-2016-01-643569 Shawker TH, Dunnick NR, Head GL, Magrath IT (1979) Ultrasound evaluation of American Burkitt’s lymphoma. J Clin Ultrasound 7(4):279–283 Biko DM, Anupindi SA, Hernandez A, Kersun L, Bellah R (2009) Childhood Burkitt lymphoma: abdominal and pelvic imaging findings. AJR Am J Roentgenol 192(5):1304–1315. https://doi.org/10.2214/AJR.08.1476 Gu J, Chan T, Zhang J, Leung AY, Kwong YL, Khong PL (2011) Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma. AJR Am J Roentgenol 197(3):W384–W391. https://doi.org/10.2214/AJR.10.5692 Schob S, Meyer J, Gawlitza M et al (2016) Diffusion-weighted MRI reflects proliferative activity in primary CNS lymphoma. PLoS One 11(8):e0161386. https://doi.org/10.1371/journal.pone.0161386 Mayerhoefer ME, Karanikas G, Kletter K et al (2015) Evaluation of diffusion-weighted magnetic resonance imaging for follow-up and treatment response assessment of lymphoma: results of an 18F-FDG-PET/CT-controlled prospective study in 64 patients. Clin Cancer Res 21(11):2506–2513. https://doi.org/10.1158/1078-0432.CCR-14-2454 Albano D, Bosio G, Re A, Pagani C, Giubbini R, Bertagna F (2018) Metabolic behavior and prognostic value of early and end of treatment 18F-FDG PET/CT in adult Burkitt’s lymphoma: the role of Deauville and IHP criteria. Leuk Lymphoma:1–8. https://doi.org/10.1080/10428194.2018.1482541 Albano D, Bosio G, Pagani C et al (2019) Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma. Eur J Nucl Med Mol Imaging 46(1):87–96. https://doi.org/10.1007/s00259-018-4173-2 Bailly C, Eugene T, Couec ML et al (2014) Prognostic value and clinical impact of (18) FDG-PET in the management of children with Burkitt lymphoma after induction chemotherapy. Front Med (Lausanne) 1:54. https://doi.org/10.3389/fmed.2014.00054 Carrillo-Cruz E, Marin-Oyaga VA, Sole Rodriguez M et al (2015) Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma. Eur J Haematol 94(1):23–30. https://doi.org/10.1111/ejh.12284 Davidson T, Priel E, Schiby G et al (2018) Low rate of spleen involvement in sporadic Burkitt lymphoma at staging on PET-CT. Abdom Radiol (NY) 43(9):2369–2374. https://doi.org/10.1007/s00261-017-1454-3 Karantanis D, Durski JM, Lowe VJ et al (2010) 18F-FDG PET and PET/CT in Burkitt’s lymphoma. Eur J Radiol 75(1):e68–e73. https://doi.org/10.1016/j.ejrad.2009.07.035 Wei WX, Huang JJ, Li WY et al (2015) Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma. Chin J Cancer 34(12):608–613. https://doi.org/10.1186/s40880-015-0057-z Cheng G, Servaes S, Zhuang H (2013) Value of (18) F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan versus diagnostic contrast computed tomography in initial staging of pediatric patients with lymphoma. Leuk Lymphoma 54(4):737–742. https://doi.org/10.3109/10428194.2012.727416 Heacock L, Weissbrot J, Raad R et al (2015) PET/MRI for the evaluation of patients with lymphoma: initial observations. AJR Am J Roentgenol 204(4):842–848. https://doi.org/10.2214/AJR.14.13181 Zelenetz A, Gordon L, J. A, A. R (2018) NCCN clinical practice guidelines: B-cell lymphomas version 1.2019 Gopal S, Gross TG (2018) How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa. Blood 132(3):254–263. https://doi.org/10.1182/blood-2018-04-844472 Burggraaff CN, de Jong A, Hoekstra OS et al (2019) Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 46(1):65–79. https://doi.org/10.1007/s00259-018-4103-3 Dunnick NR, Reaman GH, Head GL, Shawker TH, Ziegler JL (1979) Radiographic manifestations of Burkitt’s lymphoma in American patients. AJR Am J Roentgenol 132(1):1–6. https://doi.org/10.2214/ajr.132.1.1 England RJ, Pillay K, Davidson A, Numanoglu A, Millar AJ (2012) Intussusception as a presenting feature of Burkitt lymphoma: implications for management and outcome. Pediatr Surg Int 28(3):267–270. https://doi.org/10.1007/s00383-011-2982-5 Wong S, Sanchez TR, Swischuk LE, Huang FS (2009) Diffuse peritoneal lymphomatosis: atypical presentation of Burkitt lymphoma. Pediatr Radiol 39(3):274–276. https://doi.org/10.1007/s00247-008-1063-y Kluge R, Kurch L, Montravers F, Mauz-Korholz C (2013) FDG PET/CT in children and adolescents with lymphoma. Pediatr Radiol 43(4):406–417. https://doi.org/10.1007/s00247-012-2559-z Nzeh DA (1988) Atypical intrathoracic manifestations of Burkitt’s lymphoma. Pediatr Radiol 18(5):411–412 Chan O, Igwe M, Breburda CS, Amar S (2016) Burkitt lymphoma presenting as an intracardiac mass: case report and review of literature. Am J Case Rep 17:553–558 Kobayashi T, Hyodo M, Honda N (2013) Primary endobronchial Burkitt’s lymphoma in a child: a case report. Int J Pediatr Otorhinolaryngol 77(5):875–878. https://doi.org/10.1016/j.ijporl.2013.03.012 Lu R (2012) Primary burkitt lymphoma of the chest wall. Case Rep Hematol 2012:746098. https://doi.org/10.1155/2012/746098 Kaul P, Javangula K (2007) Burkitt lymphoma masquerading as cardiac tamponade. J Cardiothorac Surg 2:30. https://doi.org/10.1186/1749-8090-2-30 Janbabai G, Kayedimajd S, Alian S, Naghshvar F, Rashidi M, Farazmandfar T (2012) Bilateral breast swelling in a 23-year-old woman with Burkitt lymphoma. J Res Med Sci 17(12):1188–1191 Dozzo M, Carobolante F, Donisi PM et al (2017) Burkitt lymphoma in adolescents and young adults: management challenges. Adolesc Health Med Ther 8:11–29. https://doi.org/10.2147/AHMT.S94170 Derinkuyu BE, Boyunaga O, Oztunali C et al (2016) Imaging features of Burkitt lymphoma in pediatric patients. Diagn Interv Radiol 22(1):95–100. https://doi.org/10.5152/dir.2015.15211 Allaoui M, Benchafai I, Mahtat el M et al (2016) Primary Burkitt lymphoma of the thyroid gland: case report of an exceptional type of thyroid neoplasm and review of the literature. BMC Clin Pathol 16:6. https://doi.org/10.1186/s12907-016-0028-6 Blum KA, Lozanski G, Byrd JC (2004) Adult Burkitt leukemia and lymphoma. Blood 104(10):3009–3020. https://doi.org/10.1182/blood-2004-02-0405 Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068. https://doi.org/10.1200/JCO.2013.54.8800 Song JY, Venkataraman G, Fedoriw Y et al (2016) Burkitt leukemia limited to the bone marrow has a better prognosis than Burkitt lymphoma with bone marrow involvement in adults. Leuk Lymphoma 57(4):866–871. https://doi.org/10.3109/10428194.2015.1085529 Stein JE, Schwenn MR, Jacir NN, Harris BH (1991) Surgical restraint in Burkitt’s lymphoma in children. J Pediatr Surg 26(11):1273–1275 Jacobson C, LaCasce A (2014) How I treat Burkitt lymphoma in adults. Blood 124(19):2913–2920. https://doi.org/10.1182/blood-2014-06-538504 Smeland S, Blystad AK, Kvaloy SO et al (2004) Treatment of Burkitt’s/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian radium hospital with the use of three successive regimens. Ann Oncol 15(7):1072–1078. https://doi.org/10.1093/annonc/mdh262 Ribrag V, Koscielny S, Bosq J et al (2016) Rituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet 387(10036):2402–2411. https://doi.org/10.1016/S0140-6736(15)01317-3 Hill QA, Owen RG (2006) CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 20(6):319–332. https://doi.org/10.1016/j.blre.2006.02.001 Bernstein JI, Coleman CN, Strickler JG, Dorfman RF, Rosenberg SA (1986) Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt’s and non-Burkitt’s types). J Clin Oncol 4(6):847–858. https://doi.org/10.1200/JCO.1986.4.6.847 Sariban E, Edwards B, Janus C, Magrath I (1983) Central nervous system involvement in American Burkitt’s lymphoma. J Clin Oncol 1(11):677–681. https://doi.org/10.1200/JCO.1983.1.11.677 Eissa HM, Allen CE, Kamdar K et al (2014) Pediatric Burkitt’s lymphoma and diffuse B-cell lymphoma: are surveillance scans required? Pediatr Hematol Oncol 31(3):253–257. https://doi.org/10.3109/08880018.2013.834400 Costa LJ, Xavier AC, Wahlquist AE, Hill EG (2013) Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood 121(24):4861–4866. https://doi.org/10.1182/blood-2012-12-475558 Kim H, Park ES, Lee SH et al (2014) Clinical outcome of relapsed or refractory Burkitt lymphoma and mature B-cell lymphoblastic leukemia in children and adolescents. Cancer Res Treat 46(4):358–365. https://doi.org/10.4143/crt.2013.047 Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, Hricak H (2011) CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 258(1):41–56. https://doi.org/10.1148/radiol.10092129